Quarterly ResultAug 5, 2026, 04:21 PM
Arcus Biosciences Q2 Net Loss $91M; Revenue Down to $41M
AI Summary
Arcus Biosciences reported a net loss of $91 million for the second quarter of 2026, a significant decline from break-even in the prior year period. Total revenues for the quarter decreased to $41 million from $160 million year-over-year. For the six months ended June 30, 2026, the company posted a net loss of $219 million, compared to $112 million in the same period of 2025. The collaboration term with Gilead Sciences for new programs ended in July 2026, following Gilead's decision not to make an option continuation payment, and Gilead had previously terminated rights to the etrumadenant program in Q2 2025.
Key Highlights
- Net loss for Q2 2026 was $91 million, compared to $0 million in Q2 2025.
- Total revenues for Q2 2026 decreased to $41 million from $160 million in Q2 2025.
- Year-to-date net loss for 2026 was $219 million, compared to $112 million for the same period in 2025.
- Year-to-date total revenues for 2026 were $58 million, down from $188 million in 2025.
- Cash, cash equivalents, and marketable securities totaled $775 million as of June 30, 2026.
- Gilead's collaboration term for new programs ended on July 14, 2026, after not making the sixth-anniversary option continuation payment.
- Gilead terminated its rights to the etrumadenant program in Q2 2025, resulting in a $143 million cumulative catch-up to revenue.
- Arcus recognized $6 million in net reimbursements from the Taiho Collaboration for Q2 2026.
Price Impact
More from RCUS